https://sprucebio.com

Spruce Biosciences - Novel Therapies for Rare Endocrine DisordersDeveloping and commercializing novel therapies for rare endocrine disorders with significant unmet medical needSpruce Biosciences - Novel Therapies for Rare Endocrine Disorders Skip to Main Content   Contact Us Search: Toggle Navigation Search: Our Company About Us Our Mission Leadership Board of Directors Partnering with Spruce Contact Us Pipeline Tildacerfont Indications Adult Classic Congenital Adrenal Hyperplasia (CAH) Pediatric Classic CAH Polycystic Ovary Syndrome (PCOS) Major Depressive Disorder (MDD) Patients Patient Education Liaison Patient Resources Patient Advocacy Patient Experience Clinical Trials Studies CAHmelia CAHptain POWER Investors/Media Investor/Media Home News & Events News Releases Events Presentations Stock Information Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage Corporate Governance Documents & Charters Management Team Board of Directors Committee Composition Financials & Filings SEC Filings Annual Reports Quarterly Results IR Resources FAQs Email Alerts Contact IR Careers Our Core Values Life At Spruce Contact Us Accessibity Developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need About Spruce BioSpruce is committed to transforming the lives of patients living with endocrine and neurological disorders by developing and commercializing novel therapies where there is significant unmet medical need. Spruce’s product candidate, tildacerfont, is a CRF1 receptor antagonist currently in late-stage clinical trials in adult and pediatric patients with classic congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS). Spruce is collaborating with HMNC Brain Health to advance the development of tildacerfont as a personalized therapy option for the treatment of major depressive disorder (MDD). Learn More Learn more about Spruce’s deep commitment to patients with endocrine and neurological disorders. A Novel Approach Tildacerfont Tildacerfont is actively being studied as an innovative non-steroidal approach to treating classic CAH, PCOS, MDD and other disorders. Tildacerfont is a potent and highly selective, non-steroidal, oral antagonist of the CRF1 receptor, which is the receptor for corticotropin-releasing factor (CRF), a hormone that is secreted by the hypothalamus. Tildacerfont is designed to reduce elevated adrenocorticotropic hormone (ACTH) levels to potentially improve disease control and glucocorticoid steroid burden in patients with classic CAH. By blocking the CRF1 receptor, tildacerfont has the potential to address hyperactive brain CRF neurotransmission and aberrant functioning of the hypothalamic–pituitary-adrenal (HPA) axis in patients with MDD. Learn More NewsSeptember 3, 2024Spruce Biosciences to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceAugust 12, 2024Spruce Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate UpdatesJune 6, 2024Spruce Biosciences Recognized as a Bay Area Best Place to WorkRead All News Clinical Trials The CAHmelia clinical trials evaluating tildacerfont in adults with classic congenital adrenal hyperplasia (CAH) are closed for screening. Learn More Spruce Biosciences, Inc. 611 Gateway BoulevardSuite 740South San Francisco, California 94080 USA info@sprucebio.com ©2024 Spruce Biosciences, Inc.. All Rights Reserved. Sitemap Terms of Use Privacy Policy Cookie Policy We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies. For more information, please visit our Privacy Policy and Cookie Policy.Cookie settingsACCEPT REJECTPrivacy & Cookies Policy Close Privacy Overview This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience. Necessary Necessary Always Enabled Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information. Non-necessary Non-necessary Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website. SAVE & ACCEPT Please ensure Javascript is enabled for purposes of website accessibilityenusen-US1737127201https://sprucebio.com

Chỉnh sửa trang web của bạn?

Bạn đang làm gì thế?